Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V3-P
- Development stage
- Phase 2
- Lead developer
- Immunitor
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
V3-P is an oral tableted therapeutic vaccine developed by Immunitor LLC. It is derived from the pooled blood of patients with pancreatic ductal adenocarcinoma (PDA) and is being investigated for the treatment of inoperable pancreatic cancer. The vaccine aims to induce an immune response against pancreatic cancer cells.
- Other names
- cancer vaccine V3-Poral tableted therapeutic vaccine V3-PV3-P cancer vaccineV-3-P cancer vaccineV 3-P cancer vaccine
02
Targets
CA19-9 (Carbohydrate antigen 19-9)
Beyond the preview
Go deeper on V3-P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V3-P.